MedTrace Logo

A Trial of CM-AT in Children With Autism- Open Label Extension Study

NCT00912691 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2019-03-01

No results posted yet for this study

Summary

The purpose of this study is to determine whether CM-AT is effective in treating the core symptoms of autism.

Conditions

Interventions

DRUG

CM-AT

Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days

Sponsors & Collaborators

  • Curemark

    lead INDUSTRY

Principal Investigators

  • Eugene Arnold, MD · Ohio State University, Nisonger Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912691 on ClinicalTrials.gov